RDD Pharma

Company Overview

Snapshot

Founded in April 2008 by Nir Barak, RDD Pharma operates with 11–50 employees. The company has raised $17 million across 3 funding rounds from 6 investors. In October 2019, RDD Pharma merged with Innovate Biopharmaceuticals Inc.

Business overview

RDD Pharma is a specialty drug company focused on developing targeted pharmacological treatments for anorectal diseases such as anal fissures, fecal incontinence, and pruritus ani. The company's core technology involves repurposing existing drugs and combining them with proprietary drug-delivery methods, aiming for shorter regulatory pathways while maintaining patent protection. RDD Pharma serves the pharmaceutical and healthcare industries, operating within the drug-delivery, gastroenterology, and pharmaceuticals sectors.

Strategic signal

In October 2019, RDD Pharma merged with Innovate Biopharmaceuticals Inc., as reported by Globes. This merger signifies a strategic consolidation within the biopharmaceutical sector, indicating RDD Pharma's integration into a larger entity and potentially expanding the reach and resources for its drug development programs. For investors, this signals a successful exit strategy and validation of RDD Pharma's therapeutic pipeline.

Company Intelligence Q&A

What was a significant corporate development for RDD Pharma in late 2019?

In October 2019, RDD Pharma merged with Innovate Biopharmaceuticals Inc., a move reported by Globes and Becker's ASC.

When did RDD Pharma receive Fast Track Designation from the FDA for RDD-0315?

In February 2019, RDD Pharma received Fast Track Designation from the FDA for RDD-0315, intended for the treatment of fecal incontinence in spinal cord injury patients.

What was a key regulatory milestone for RDD Pharma's RDD-0315 program in 2018?

In July 2018, RDD Pharma announced IND clearance to advance RDD-0315 for the treatment of fecal incontinence in patients with spinal cord injury.

Which investors participated in RDD Pharma's Series B funding round?

In November 2017, RDD Pharma raised $9.5 million in Series B funding with participation from OrbiMed.

Which investor participated in RDD Pharma's Series A funding round?

In July 2012, RDD Pharma secured Series A funding from OrbiMed Healthcare Fund Management.